Research On The Direct Investment Of Yunnan Biomedical Industry To Southeast Asia

The bio-pharmaceutical industry has become one of the most rapid growth industries.Since 2005,the global bio-pharmaceutical market has grown more than 10%,and the domestic market growth has been more than 25%.Domestic growth rate is nearly twice as fast as that of the world.The revenue of China bio-pharmaceutical industry in 2016 reached 1532.9 billion yuan,up 10.04%,much higher than that of other manufacturing industries.And yet,behind achievements,various problems have become more and more obvious.Investment risk caused by investment environment is worth attention.However,although there are many research concerning investment environment risk and biomedical research in southeast Asia,the combination of the two is rare and lack of practicability and operability.It is difficult to play an effective guidance role in the bio-pharmaceutical investment practice in southeast Asia.Therefore,strengthening the research on the investment environment of bio-pharmaceutical industry is of great,significance and practical necessity.This paper takes the development of the bio-pharmaceutical industry of Yunnan in ASEAN as the research object.The author not only uses the traditional standard research,but also introduces the empirical research method.To better assess the investment risk of Yunnan bio-pharmaceutical industry to southeast Asia,this paper uses the data of investment destination to reflect the impact of the investment environment.Research results show that political environment,economic environment,social environment and legal environment of ASEAN countries influence the direct investment of biomedical industry of Yunnan province.The analysis results could also help relevant government departments formulate reasonable policies and lead Yunnan biomedical industry to invest in southeast Asia in a healthy way.